Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine Adjunct in MDD
NCT03739203Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2018
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of cariprazine in major depressive disorder (MDD) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Change From Baseline in Montgomery-Åsberg Depression Rating Scale Total Score at 6 weeks. Started Nov 2018; status: completed.
02
Drugs
cariprazine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03739203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739203.